*Together with MAIA Biotechnology (NYSE: MAIA)
Good day, 360 –
Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street!
FOCUS LIST🔎
MGOL – Up over 40% in pre-market after reporting earnings, 10x year over year sales growth
SLDB – Up over 25% in pre after receiving IND clearance from FDA for DMD gene therapy
CMMB – Up over 80% in pre after receiving FDA Fast Track designation for its Primary Sclerosing Cholangitis treatment
SPOTLIGHT💡
*A Message on Behalf of MAIA Biotechnology
The markets continue to defy the skeptics, and power higher seemingly every day lately – making it especially tricky to trade in this Market!
But… as we have been looking at charts this week, there is one that stands out to us:
🔥MAIA Biotechnology, Inc. (NYSE: MAIA)🔥
We brought this stock to your attention about a month ago, and it made a great move, if you were watching it then.
Now we’re seeing some very similar patterns appear again. From the chart, we are seeing multiple GO signals once again and the stock has been building a base around $1.80.
If you look at this chart, you can almost “feel” the coiling action happening now, right? When MAIA decides to break out of this range, it could be really explosive.
The outlook is BULLISH and insider confidence remains high, as over the last year, company insiders bought shares 79 times and didn’t have a single sell reported, even during the post-January drawdown.
So many reasons to pull up MAIA on your platform right now, do your own due diligence and see if it makes sense to you!
*Sponsored by Sica Media. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
HOTLIST🔥
MGOL – Up over 40% in pre-market after reporting earnings, 10x year over year sales growth
MGO Global, Inc. (MGOL) operates as a lifestyle brand portfolio company. The company is involved in the fashion design, brand development and management, sourcing and manufacturing, licensing, IP protection, corporate finance, consumer engagement and experience, e-commerce, and retail sales and marketing activities related to the Messi brand.
In the after-hours, MGOL reported Q3 EPS of -$0.17, down from -$0.06 YoY and sales of $1.47million up from $140.19thousand a year ago.
Traders loved the 1000% sales increase and the stock traded up over 40% in the pre-market.
The $0.70 area has acted has support so far in the pre-market and will be an important level to watch.
Above it, Targets to the upside are $0.82, $0.90, $1, and then the pre-market high at $1.09. Beyond that, $1.20 and $1.40 come into play.
Below $0.70, there is potential support at $0.60 and then a gap to fill at $0.5050.
SLDB – Up over 25% in pre after receiving IND clearance from FDA for DMD gene therapy
Solid Biosciences Inc. (SLDB) is a life science company that engages in developing therapies for neuromuscular and cardiac diseases in the United States.
In the after-hours yesterday, the company announced that it had received FDA clearance for its Investigational New Drug (IND) application for SGT-003, the company’s next-generation Duchenne Muscular Dystrophy gene therapy candidate.
The clearance gives SLDB the go ahead in preparation for its planned Phase 1/ 2 trial.
The stock traded up over 25% in pre-market after the news release.
The $2.60 area has acted as support in the after-hours and pre-market and will be an important level to watch.
Above it, targets to the upside are $2.80, $2.95, $3 and then the pre-market high at $3.19. Beyond that, $3.50 and $3.80 come into play.
Below $2.60, there is potential support at $2.47 and then a gap to fill at $2.13.
CMMB – Up over 80% in pre after receiving FDA Fast Track designation for its Primary Sclerosing Cholangitis treatment
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company that discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases.
This morning, the company announced that the U.S. Food and Drug Administration (FDA) had granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death.
The stock traded up over 80% in pre market after the news hit this morning.
$1.15 has acted as resistance in the pre-market and will be an important level to watch.
Above it, the first target to the upside is the pre-market high at $1.17.
Beyond that, $1.20, $1.40, $1.50 and $1.75 come into play.
Below $1.15, there is potential support at $1.05, $1, $0.90, $0.85 and a gap to fill at $0.61.
Magic Links for more great trading resources (new!):
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
*PAID ADVERTISEMENT. Raging Bull has currently been paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023. Raging Bull has previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of MAIA Biotechnology, Inc, increased trading volume, and possibly an increased share price of MAIA Biotechnology, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in MAIA Biotechnology, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.
FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
